The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology
Robert S RosensonChristopher P Cannon

Abstract

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups. Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute coronary syndrome, multivessel coronary artery disease, or peripheral arterial disease. Commonly observed profound reductions in LDL-C to levels <25 mg/dl have been accompanied by even lower rates of atherosclerotic cardiovascular disease events, thus supporting the concept that there may be no lower limit for LDL-C. Aggressive LDL-C lowering with fully human PCSK9 monoclonal antibodies has been accompanied by a safety profile that has been very favorable. On the basis of clinical trial evidence, LDL lowering with PCSK9 inhibitors is recommended for high-risk patients with LDL-C levels ≥70 mg/dl on maximally tolerated oral therapies including statins and/or ezetimibe.

Citations

Oct 18, 2018·The International Journal of Neuropsychopharmacology·Falk W Lohoff
Feb 1, 2019·Circulation Research·Robert S RosensonWolfgang Koenig
Feb 1, 2019·Circulation Research·Robert A Hegele, Sotirios Tsimikas
Aug 30, 2019·British Journal of Pharmacology·Toshiyuki Nishikido, Kausik K Ray
Mar 3, 2020·The Annals of Pharmacotherapy·Natalia Shcherbakova, Shane Desselle
Jul 28, 2020·Expert Opinion on Biological Therapy·Amir Mohammad MalvandiAlberico Luigi Catapano
Sep 24, 2020·Expert Opinion on Drug Metabolism & Toxicology·Svetlana MoşteoruMaciej Banach
Oct 12, 2019·NPJ Genomic Medicine·Julieta Lazarte, Robert A Hegele
Nov 6, 2018·International Journal of Molecular Sciences·Asier Benito-VicenteCesar Martin
Dec 24, 2019·Expert Opinion on Investigational Drugs·Amit RoutPaul A Gurbel
Dec 18, 2019·Korean Circulation Journal·Wes SpillerSun Ha Jee
Aug 18, 2020·Journal of Multidisciplinary Healthcare·Sergio MinelliMaria Rosa Montinari
Sep 27, 2020·Cardiovascular Drugs and Therapy·Stephani C WangRobert S Rosenson
Jun 17, 2020·Therapeutic Advances in Chronic Disease·Eun Ji Kim, Anthony S Wierzbicki
Jun 27, 2019·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Rita Del PintoClaudio Ferri
Mar 9, 2019·Nature Reviews. Cardiology·Magnus BäckPetri T Kovanen
Sep 18, 2020·Journal of Drug Assessment·Rasha KaddouraAmar M Salam
Oct 31, 2019·European Heart Journal·Jacqueline S Dron, Robert A Hegele
Oct 17, 2018·Current Diabetes Reports·Om Ganda
Mar 21, 2019·Annals of Clinical Biochemistry·L Renee RuhaakChrista M Cobbaert
Dec 29, 2020·Neurología : publicación oficial de la Sociedad Española de Neurología·A Gil-NúñezE Palacio
Jul 3, 2020·The Journal of Investigative Dermatology·Michael S GarshickNehal N Mehta
Dec 29, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Camilo BretonJames M Wilson
Dec 9, 2020·Metabolism: Clinical and Experimental·Eftaxia-Konstantina ValantiDespina Sanoudou
Oct 28, 2020·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toru SuzukiKouichi Tamura
Dec 6, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Farzahna MohamedFrederick J Raal
Feb 21, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lili WangJames M Wilson
Mar 8, 2021·Molecular Biology Reports·Xin Su
Mar 16, 2021·Journal of Lipid Research·Robert S Rosenson
Apr 4, 2021·Biomedicines·Juan M Suárez-RiveroJosé A Sánchez-Alcázar
May 1, 2021·Journal of Clinical Medicine·Gabriella IannuzzoFrancesco Giallauria
Apr 29, 2019·Journal De Médecine Vasculaire·J P Laroche
May 20, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Pablo Pérez-Martínez, Francisco Pérez-Jiménez
May 22, 2021·Journal of the American College of Cardiology·Clint L MillerJason C Kovacic

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.